Price
No data yet.
Social Signal Score
Analyst Ratings
Company Profile
- CEO
- Travis Murdoch
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Beta
- 0.00
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
BRVEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-55.32%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·19d ago·Positive
Braveheart Bio to Participate in Stifel Cardiometabolic Forum SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Stifel Virtual Cardiometabolic Forum, being held September 30. Management will participate in a fireside chat on Wednesday, September 30, 2…
View source ↗ - Newsfool.com·56d ago·Negative
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success? The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026. The acquisition increased the total equity position by 5%, resulting in a 0.87% ownership stake.
View source ↗ - Newsfool.com·56d ago·Positive
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors? The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close. Director Viehbacher increased his direct equity holdings by 16% through this acquisition.
View source ↗ - Newsfool.com·56d ago·Positive
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors? Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.
View source ↗
Earnings
Typical surprise -193.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Sep 8$-2.51 vs $2.69miss
Estimates and results for BRVE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BRVE officers and directors.
- Bought
- $159.0m
- Sold
- —
13 trades
0 trades
- Ah Bio Fund Iv, L.p.bought
- Chimovits Erezbought
- Chimovits Erezbought
- Orbimed Advisors Llcbought
- Orbimed Advisors Llcbought
- Forbion Growth Opportunities Fund Iii Cooperatief U.a.bought
- Forbion Growth Opportunities Fund Iii Cooperatief U.a.bought
- Rickey James Paulbought
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BRVE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.